Bavarian Nordic Reports Strong 2025 Results, Preps Leadership Transition
Event summary
- Bavarian Nordic reported DKK 6,244 million in revenue for 2025, exceeding guidance of DKK 6,000 million, with EBITDA margin at 28% (41% including special items).
- CEO Paul Chaplin announced his departure later in 2026, marking a leadership transition after a decade of strategic transformation.
- The company launched a share buy-back program for up to DKK 500 million in 2026 and secured a USD 22.5 million order from Canada for mpox and smallpox vaccines.
- Bavarian Nordic expects 2026 revenue of DKK 5,000–5,200 million, with Travel Health surpassing Public Preparedness for the first time.
The big picture
Bavarian Nordic’s 2025 results confirm its strategic shift toward Travel Health, now surpassing Public Preparedness revenues. The leadership transition and share buy-back signal confidence in the company’s mid-term growth ambitions, though normalization of outbreak-driven revenues poses a challenge. The expansion of the chikungunya vaccine’s market reach through new partnerships underscores the company’s focus on scaling its core products.
What we're watching
- Leadership Transition
- The impact of Paul Chaplin’s departure on Bavarian Nordic’s strategic direction and execution of its Travel Health expansion.
- Market Normalization
- Whether the company can sustain growth as Public Preparedness revenues normalize post-outbreak years.
- Vaccine Scaling
- The pace at which the chikungunya vaccine’s manufacturing capacity scales through the Serum Institute of India partnership.
Related topics